Biotech · Private company
Synthekine
Track this companyFree. Adds Synthekine to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- carboplatinPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab KEYTRUDA®Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- pemetrexedPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- STK-012Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- STK-009Phase 1 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- STK-009Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- SYNCAR-001Phase 1 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- SYNCAR-001Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic DiseasePHASE1 · ACTIVE_NOT_RECRUITING · started Apr 29, 2025ClinicalTrials.gov NCT06544330 · fetched Nov 12, 2026
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 23, 2023ClinicalTrials.gov NCT05665062 · fetched Nov 12, 2026
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersPHASE1_PHASE2 · RECRUITING · started Jan 25, 2022ClinicalTrials.gov NCT05098132 · fetched Nov 12, 2026